drug

OTX-TKI

1 story · latest Aug 3, 2026

Status: Investigational
Trials: 1 registered trial in coverage

Relationships

Developed by Ocular Therapeutix, Inc.

Timeline

Ocular Therapeutix targets Q4 2026 AXPAXLI NDA filing for wet AMD after FDA meeting

Aug 3Quarterly updateOcular Therapeutix, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.